Tirzepatide expands OSA conversation

Tirzepatide is pushing sleep apnea deeper into obesity care, with new data, a new pen device, and new coverage fights all landing at once. (fda.gov) (ajmc.com) (pharmacytimes.com) Obstructive sleep apnea happens when the upper airway repeatedly collapses during sleep, causing breathing pauses and drops in oxygen. On December 20, 2024, the Food and Drug Administration approved Zepbound, the tirzepatide brand, as the first drug treatment for moderate to severe obstructive sleep apnea in adults with obesity. (fda.gov) That approval rested on two randomized, double-blind, placebo-controlled studies in 469 adults without type 2 diabetes. One trial enrolled people using positive airway pressure, and the other enrolled people who could not or would not use it. (fda.gov) In the phase 3 SURMOUNT-OSA program, tirzepatide cut the apnea-hypopnea index, the hourly count of breathing disruptions, by 25.3 events per hour more than placebo in one trial and 29.3 events per hour more than placebo in the other at 52 weeks. Participants on tirzepatide also lost 16.1% to 17.3% of body weight, versus 1.6% and 2.3% with placebo. (nejm.org) The drug works by activating glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, gut-hormone pathways that reduce appetite and food intake. The Food and Drug Administration said the sleep apnea benefit is tied to weight reduction. (fda.gov) Now the delivery options are changing too. On February 23, 2026, AJMC reported that the Food and Drug Administration cleared a 4-dose Zepbound KwikPen, giving patients one month of once-weekly treatment in a single device. (ajmc.com) (accessdata.fda.gov) The updated label lists 5 mg, 10 mg, and 15 mg once weekly for weight reduction and long-term maintenance, and 10 mg or 15 mg once weekly for obstructive sleep apnea. The same January 2026 label update added administration instructions for the KwikPen presentations. (accessdata.fda.gov) Access is moving in the opposite direction for some patients. CVS Health said on May 1, 2025, that its pharmacy benefit manager would drop Zepbound from its preferred formulary starting July 1, 2025, and prioritize coverage of Wegovy instead. (pharmacytimes.com) Pharmacy Times said that shift can force patients already taking tirzepatide to switch drugs, even after head-to-head SURMOUNT-5 results showed greater average weight loss with tirzepatide than injectable semaglutide over 72 weeks. AJMC reported mean losses of 20.2%, or 50 pounds, with tirzepatide and 13.7%, or 33 pounds, with semaglutide. (pharmacytimes.com) (ajmc.com) At the 2026 American Pharmacists Association meeting in Los Angeles, Emily Eddy of Ohio Northern University told pharmacists the class has expanded from diabetes into obesity, sleep apnea, liver disease, kidney disease, and other metabolic conditions. The sleep apnea conversation is now less about a sleep-lab machine alone and more about who can get, keep, and pay for a weight-loss drug that also changes nighttime breathing. (pharmacytimes.com)